The recently issued patent, which is the second US patent issued to ProLynx, focuses on drugs covalently coupled via the company’s patented beta-eliminative linkers to multiple sites on a dendrimer.
According to the company, a dendrimer is a synthetic polymer characterized by repeated chain branching originating from a central core, giving rise to several chain endings available for drug attachment.
ProLynx co-founder and chief scientific officer Gary Ashley said dendrimers provide a potential improvement over standard PEGylation approaches, as they can carry a much higher drug payload.
"Together with our linkers, they offer slow release of a large amount of drug," Ashley said.
The company is focused on developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules.
ProLynx is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies and also to out-license the long lasting drug conjugates in its pre-clinical product portfolio.